{"id":"auto-cd34-cells","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Mobilization-related adverse events"},{"rate":null,"effect":"Transient fever or flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CD34+ cells are hematopoietic stem and progenitor cells that can differentiate into various cell types and secrete paracrine factors that promote angiogenesis, reduce inflammation, and support tissue healing. In Lisata's approach, these autologous cells are mobilized using a proprietary mobilization regimen, collected via apheresis, and reinfused into patients to enhance regenerative capacity in damaged or ischemic tissues. The mechanism leverages the cells' inherent ability to home to injury sites and promote vascular and tissue recovery.","oneSentence":"Auto-CD34+ cells are autologous CD34+ hematopoietic stem cells mobilized and collected from a patient's own bone marrow or peripheral blood, then reinfused to promote tissue regeneration and repair.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:06.544Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Critical limb ischemia"},{"name":"Severe peripheral artery disease"}]},"trialDetails":[{"nctId":"NCT03818763","phase":"PHASE1","title":"Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2020-04-29","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT05265767","phase":"PHASE1","title":"Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A","status":"COMPLETED","sponsor":"Christian Medical College, Vellore, India","startDate":"2022-04-01","conditions":"Hemophilia A","enrollment":6},{"nctId":"NCT06425276","phase":"PHASE4","title":"Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation","status":"COMPLETED","sponsor":"CASI Pharmaceuticals (China) Co., Ltd.","startDate":"2020-07-24","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT00114530","phase":"PHASE2, PHASE3","title":"Scleroderma: Cyclophosphamide or Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-06","conditions":"Scleroderma, Systemic, Sclerosis, Autoimmune Disease","enrollment":75},{"nctId":"NCT01746173","phase":"PHASE2","title":"CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-07","conditions":"T-cell Non-Hodgkin Lymphoma","enrollment":5},{"nctId":"NCT00075829","phase":"PHASE3","title":"Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-12","conditions":"Multiple Myeloma","enrollment":710},{"nctId":"NCT00300053","phase":"PHASE2","title":"ACT34-CMI -- Adult Autologous CD34+ Cells","status":"COMPLETED","sponsor":"Lisata Therapeutics, Inc.","startDate":"2006-04","conditions":"Myocardial Ischemia","enrollment":321},{"nctId":"NCT01508910","phase":"PHASE3","title":"Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina","status":"COMPLETED","sponsor":"Lisata Therapeutics, Inc.","startDate":"2012-04","conditions":"Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease","enrollment":291},{"nctId":"NCT00545610","phase":"","title":"ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)","status":"COMPLETED","sponsor":"Lisata Therapeutics, Inc.","startDate":"2007-10","conditions":"Myocardial Ischemia","enrollment":150},{"nctId":"NCT00481832","phase":"PHASE2","title":"Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":50},{"nctId":"NCT00185614","phase":"PHASE2","title":"Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma","status":"COMPLETED","sponsor":"Wen-Kai Weng","startDate":"2000-08","conditions":"Blood Cancer, Multiple Myeloma","enrollment":63},{"nctId":"NCT00899847","phase":"PHASE2","title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma","enrollment":9},{"nctId":"NCT01181271","phase":"PHASE2","title":"Tandem Auto-Allo Transplant for Lymphoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-08","conditions":"Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma","enrollment":42},{"nctId":"NCT00028600","phase":"PHASE2","title":"Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-11","conditions":"Multiple Myeloma, Plasma Cell Neoplasm","enrollment":60},{"nctId":"NCT00230035","phase":"PHASE2","title":"Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT00577668","phase":"PHASE2","title":"A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2007-04","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT00186680","phase":"PHASE1, PHASE2","title":"CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant","status":"COMPLETED","sponsor":"Stanford University","startDate":"1996-09","conditions":"Breast Cancer","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Auto-CD34+ cells","genericName":"Auto-CD34+ cells","companyName":"Lisata Therapeutics, Inc.","companyId":"lisata-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Auto-CD34+ cells are autologous CD34+ hematopoietic stem cells mobilized and collected from a patient's own bone marrow or peripheral blood, then reinfused to promote tissue regeneration and repair. Used for Critical limb ischemia, Severe peripheral artery disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}